Navigation Links
Arena Pharmaceuticals Announces Second Quarter 2008 Financial Results and Recent and Second Quarter Highlights
Date:8/5/2008

change Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Arena Pharmaceuticals, Inc.

Condensed Consolidated Statements of Operations

(In thousands, except per share amounts)

Three months ended Six months ended

June 30, June 30,

2008 2007 2008 2007

(unaudited) (unaudited)

Revenues

Contract manufacturing $2,000 $-- $4,019 $--

Collaborative agreements 645 4,811 1,235 9,722

Total revenues 2,645 4,811 5,254 9,722

Operating Expenses

Cost of contract manufacturing 2,290 -- 4,620 --

Research and development 56,410 40,860 103,975 76,615

General and administrative 7,153 6,840 16,014 11,763

Amortization of acquired

technology 384 384 768 768

Total operating expenses 66,237 48,084 125,377 89,146

Interest and other income and

expenses, net (1,677) 4,665 389 8,921

Net loss (65,269) (38,608) (119,734) (70,503)

Dividends on redeemable

convertible preferred stock (546) (524) (1,086) (1,038)

Net loss allocable to common

stockholders $(65,815) $(39,132) $(120,820) $(71,541)

Net loss per share allocable

to common stockholders,

basic and diluted $(0.89) $(0.64)
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Arena Pharmaceuticals to Report Second Quarter 2008 Financial Results and to Host Conference Call and Webcast on Tuesday, August 5, 2008
2. Arena Pharmaceuticals to Present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference
3. ThreeWire Expands Presence in the Pharmaceutical Arena
4. Arena Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference
5. Arena Pharmaceuticals Announces First Quarter 2008 Financial Results
6. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
7. Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results
8. Arena Pharmaceuticals to Report Fourth Quarter and Full Year 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, February 27, 2008
9. Arena Pharmaceuticals to Present at the BIO CEO & Investor Conference
10. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc.
11. Arena Pharmaceuticals Enters Into Strategic Agreements for the Manufacture of Pharmaceutical Material, Including Lorcaserin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... MARINO, Calif. , May 23, 2013 /PRNewswire/ ... today a strategic alliance with DAK Renewable Research ... the corn oil yield. VG Energy is a ... (OTC Pink: VGLS). VG Energy,s exclusively ... to increase the oil yield in plants, possessing ...
(Date:5/23/2013)... EXTON, Pa. , May 23, 2013 /PRNewswire/ ... leading research and advisory firms for specialized biopharmaceutical ... gastroenterologists, hepatologists, and infectious disease specialists reported that ... warehousing patients (e.g., intentionally delaying treatment) in anticipation ... physicians than six months ago, when only 6 ...
(Date:5/23/2013)... Md. , May 23, 2013 Northwest ... biotechnology company developing DCVax ® personalized immune therapies ... use its exhibit at this year,s American Society Of ... to highlight its leadership role in immune therapy.  ... The ASCO annual meeting is the pre-eminent conference focused ...
(Date:5/23/2013)... SAN DIEGO , May 23, 2013  Verenium ... biotechnology company focused on the development and commercialization of ... , Chief Financial Officer, will present at two ... Mr. Black will present at the Second Annual ... at the Grand Hyatt Hotel in New York City.  ...
Breaking Biology Technology:VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 2VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 3The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 2The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 3NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 2NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 3Verenium To Present At Two Upcoming Conferences 2Verenium To Present At Two Upcoming Conferences 3
... First in Europe To Treat Patients With New ... Focused Radiation Therapy, ... first European patient has been treated in the company,s,pivotal global clinical ... of age-related macular degeneration (AMD). Wet AMD,is the most progressive form ...
... Nektar,Therapeutics (Nasdaq: NKTR ) announced today that it ... Focus on Healthcare Conference in New,York at the Millennium ... ET., The presentation and Q&A session will be ... on the Investor Relations, Events,Calendar section of the Nektar ...
... Technologies, Inc.,a developer of NanoReactor droplet-based microfluidic ... as President and Chief,Executive Officer. McNary will ... driving RainDance Technologies, vision and the upcoming,commercial ... the Life,Sciences and other related markets., ...
Cached Biology Technology:First European Patient Treated in CABERNET Trial With Novel Treatment for Wet AMD 2First European Patient Treated in CABERNET Trial With Novel Treatment for Wet AMD 3RainDance Technologies Appoints McNary President and CEO 2RainDance Technologies Appoints McNary President and CEO 3
(Date:5/23/2013)... (May 23, 2013) A new report from ... for helping pupils engage in at least 60 minutes ... day. , No more than half of American youth ... of vigorous or moderate intensity physical activity daily, according ... "Because children are in school for nearly half of ...
(Date:5/23/2013)... Wis. In an age when microbial pathogens are ... tamp down infection, a team of Wisconsin scientists has ... curbing the bacteria that cause staph infections. , Writing ... Society , a group led by University of Wisconsin-Madison ... with the "quorum sensing" behavior of Staphylococcus aureus ...
(Date:5/22/2013)... major new effort to educate the public and decision ... clean water that looms ahead in the 21st century. ... current edition of Chemical & Engineering News , ... the world,s largest scientific society. , Bassam Z. Shakhashiri, ... Ph.D., explain that shortages of reliable supplies of fresh ...
Breaking Biology News(10 mins):Schools should provide students with daily physical activity, IOM recommends 2University of Wisconsin chemists find new compounds to curb staph infection 2
... cells in a growing embryo must chart their course to distant ... yet to surface. In a study published in the current issue ... Studies have recovered a key signal that guides motor neurons ... find their way down the length of limbs such as arms, ...
... oblivious to the odor in the locker room after a ... of sweat. Research by Prof. Doron Lancet and research student ... in PLoS Biology, has now shown that this difference is ... takes a back seat to our other senses, but humans ...
... ... Informed and In Touch, WALL, N.J., Nov. 20 ... biometric,identification and wireless public safety, was featured in a recent,televised report ... the ABC affiliate in Oklahoma City. The,November 18th report highlighted the ...
Cached Biology News:Salk scientists identify key nerve navigation pathway 2Salk scientists identify key nerve navigation pathway 3BIO-key(R) PocketCop(R) Project 'Leading the Nation' According to Televised Report 2
... The Helios gene gun low-pressure system, 220-240 ... biomaterials into cells. This handheld device employs an ... other biomaterial-coated gold microcarriers from the inner wall ... cells. This system can be used for in ...
... Hybridization Wash Pack provides optimized blocking ... Preparation Quality Clarifier: Ready-to-use wash solutions ... SigmaScreen(tm) APS Coated Slides for Microarrays ... Hybridization Blocking Buffer: 1L • Microarray ...
Mouse polyclonal antibody raised against a partial recombinant MHC2TA. NCBI Entrez Gene ID = 4261...
Mouse monoclonal antibody raised against a partial recombinant JRKL. NCBI Entrez Gene ID = JRKL...
Biology Products: